TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xlife Sciences Ltd. ( (CH:XLS) ) has shared an update.
Xlife Sciences AG announced progress in the NASDAQ listing process for its portfolio company, VERAXA Biotech AG, following a US government shutdown that delayed SEC responses. VERAXA, which is merging with Voyager Acquisition Corp., has submitted a revised Form F-4 to the SEC, with the NASDAQ listing expected to complete in the first quarter of 2026, marking a significant step in its development as a leader in oncology therapeutics.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss company that serves as an incubator and accelerator for the development and commercialization of promising research projects in the life sciences sector. It focuses on bridging the gap from research and development to healthcare markets by selecting projects in technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health.
Average Trading Volume: 1,744
Technical Sentiment Signal: Sell
Current Market Cap: CHF97.47M
See more insights into XLS stock on TipRanks’ Stock Analysis page.